--- title: "Brain Interfaces Without the Knife—Do They Stand a Chance?" date: 2026-11-04 category: Brain–Computer Interface site: NeuroAI canonical: https://neuroai.site/a/na-noninvasive-03-1104 language: en --- # Brain Interfaces Without the Knife—Do They Stand a Chance? > When people think of brain-computer interfaces, many picture open-skull surgery and implanted electrodes. Yet there is a gentler path: no incision, no knife—letting signals slip quietly in and out of When people think of brain-computer interfaces, many picture open-skull surgery and implanted electrodes. Yet there is a gentler path: no incision, no knife—letting signals slip quietly in and out of the brain through the scalp or through sound waves. More and more Chinese teams are opening this path, giving those who fear cranial surgery another option. After all, for the vast majority of people, being willing to wear a device on the head is far easier than being willing to have a knife taken to it. Gentleness itself is a kind of competitiveness. ## A Hat or a Surgery By how they collect signals, brain-computer interfaces fall roughly into three types. The non-invasive type is like "a hat" placed on the scalp—safe and non-invasive, but with limited signal precision. The invasive type implants electrodes into the cortex, giving clear signals but requiring one to bear the trauma. The semi-invasive type sits between the two, balancing safety and quality. The three routes have no absolute superiority or inferiority; it depends on the scenario. To read deep individual neurons, the invasive route is often necessary; for basic attention training or sleep monitoring, the non-invasive route already suffices. Choosing a route is essentially a trade-off between risk and reward. Common consumer sleep headbands and focus-training devices mostly belong to the non-invasive type. They have a low threshold and are easy to use, yet they can hardly read deep neural activity. This also explains why the non-invasive route fits wellness consumption, while medical-grade fine control still depends on the route closer to the brain. The non-invasive route is more like an "entry-level" technology: it first leads people through the door of brain-computer interaction, with low cost and risk, suited to broad exploratory coverage. When fine control is needed, one then considers a deeper route. ## A New Player on the Ultrasound Route On January 1, 2026, Gestalt (Chengdu) Technology Co., Ltd. was founded, launching a new non-invasive route built on ultrasound technology. Ultrasound can precisely regulate specific brain regions without opening the skull, offering fresh ideas for the non-invasive treatment of brain diseases. On its founding day, the company set its goal on "next-generation whole-brain signal reading and writing," with ambitions not only in treatment but also in building a platform. But whether the platform can grow is, in the end, still a question for clinical outcomes to answer. The imaginative space of this route lies in "free regulation." Unlike an implant that carries lifelong hardware risk, it is like having an imaging scan—intervening on brain regions and neural circuits at multiple targets. Whether it works will still depend on clinical and regulatory feedback. Ultrasound is a typically Chinese new route. Rather than following the invasive mainstream, it takes a different tack in physical means, using mechanical waves to "talk" with neurons. Diversity of thinking itself is a sign of industrial vitality. New players keep entering the field, meaning the route is no longer defined by a single company; competition will force more possibilities out. This is exactly what makes the non-invasive track worth watching. What makes ultrasound so promising is that it can focus energy onto a specific spot inside the skull without cutting anything. For brain-disease patients, this means treatment may be as easy as having a scan—precisely what makes the non-invasive approach especially appealing. Of course, ultrasound regulation has its own difficulty: the energy must be precise—neither too weak to work, nor too strong to harm tissue. The calibration of dosage and target is the hard bone this route must chew. ## The All-Acoustic Clinical Exploration In March 2026, the all-acoustic brain-computer interface system developed by a Hong Kong Polytechnic University team drew attention. Through precise ultrasound neuromodulation, it has cooperated with institutions including Huashan Hospital in Shanghai on clinical research, opening a new possible path for the treatment of Parkinson's disease. "All-acoustic" means using sound waves as much as possible to complete both signal reading and stimulation, further reducing trauma. For patients who fear open-skull surgery, such an approach is naturally friendlier, moving the threshold of choice a notch toward the general public. The essence of Parkinson's disease is the dysfunction of specific circuits inside the brain. The all-acoustic route targets exactly these circuits, using sound waves for non-invasive regulation, gentler than open-skull surgery—which is why it is favored. Yet one must also see that sound waves attenuate and scatter when passing through the skull, making signal controllability harder to manage than with implanted electrodes. Every small clinical step forward is backed by repeated engineering refinement. Huashan Hospital, a leading domestic neurosurgery institution, is willing to take on such exploration, which also shows the clinical side's open attitude toward new schemes. The caution on the operating table and the curiosity about new technology are not contradictory here. Thinking of the treatment as easy is not the same as thinking the difficulty is small. From a single regulation in the lab to a repeatable protocol in the clinic, there are still several hurdles to clear: dosage, target, and long-term safety. ## The Picture of China and the U.S. Running Side by Side Overall, the United States maintains a lead in invasive technology, while China runs side by side with the U.S. in the non-invasive field and has taken the lead in achieving commercialization on the semi-invasive route. This staggered competition makes the global brain-computer interface a lively landscape of parallel routes. The semi-invasive route is seen as having greater commercial potential at this stage precisely because it finds a balance between "safe enough" and "clear enough." It does not penetrate brain tissue yet sits closer to the signal source than scalp-external solutions, making it easier to scale up in hospital settings. One must stay sober: "running side by side" is not "fully ahead." On hard metrics such as channel scale and system integration, a gap with leading players remains. The non-invasive advantage lies in safety and reach, its short board in precision, which decides it fits medicine rather than consumer use in the short term. This also reminds us that evaluating a technology should not only look at "whether it exists" but also at "whether it works well." The non-invasive advantage in reach can only truly pay off after its precision short board is shored up. ## Medicine Lands First, Consumer Still Early Putting the three routes together, the conclusion is actually clear: the smaller the trauma, the easier it is to spread; the higher the precision, the harder to leave the medical scenario. What actually has the conditions to land today are rigid medical applications such as rehabilitation, Parkinson's, and sleep disorders. As for a "mind-controlled toy" that everyone can wear, we will probably have to wait a while longer. However fast the technology runs, it must clear three hurdles—precision, cost, and trust. Does the knife-free brain-computer interface stand a chance? It does, but its stage is built in the clinic, not in the living room. In the end, the three routes of brain-computer interfaces are not a fight to the death but a division of roles. The non-invasive opens the door, the invasive does the job precisely, and the semi-invasive finds the balance in between. Each has its own stage and its own audience. **Disclaimer: This article is based on publicly available information and is for reference only. It does not constitute investment advice.** --- Published by NeuroAI (https://neuroai.site/) — https://neuroai.site/a/na-noninvasive-03-1104 Free to quote with attribution and a link to the original.